XML 14 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 259,393 $ 80,428
Marketable securities 389,434 282,046
Interest receivable 822 682
Accounts receivable 39,487 36,909
Prepaid expenses and other current assets 11,158 5,408
Total current assets 700,294 405,473
Marketable securities, non-current 45,761 21,832
Property and equipment, net 35,282 29,926
Intangible assets 55,569 53,156
Goodwill 40,984 39,273
Operating lease right-of-use assets 71,637 77,289
Other non-current assets 12,683 9,067
Restricted cash 1,500 1,500
Total assets 963,710 637,516
Current liabilities:    
Accounts payable and accrued liabilities 17,897 17,556
Accrued compensation and employee benefits 17,873 13,605
Deferred revenues 87,791 38,711
Total current liabilities 123,561 69,872
Deferred revenues, non-current 267,903 81,432
Long-term portion of lease liabilities 38,259 41,192
Deferred income tax 6,868 6,570
Other non-current liabilities 6,238 5,711
Total liabilities 442,829 204,777
Commitments and contingencies
Stockholders' equity:    
Preferred stock 0 0
Common stock 1,412 1,160
Additional paid-in capital 1,255,823 1,090,828
Accumulated deficit (737,377) (656,985)
Accumulated other comprehensive income (loss) 1,553 (2,449)
Total Sangamo Therapeutics, Inc. stockholders' equity 521,411 432,554
Non-controlling interest (530) 185
Total stockholders' equity 520,881 432,739
Total liabilities and stockholders' equity $ 963,710 $ 637,516